English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 10 March 2023, 15:04 JST
Share:
    

Source: Eisai
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award

TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).


The "J-Win Diversity Award" has been held annually since 2008 with the aim of accelerating the promotion of diversity and inclusion (D&I) in Japanese companies by awarding leading businesses that are promoting D&I. Among the Company Prizes, Eisai was selected as the winner of the "Basic Achievement Grand Prize", which is the highest award within the "Basic Category" covering businesses who demonstrate the significance and purpose of female empowerment, developing systems and frameworks with set goals, and are taking action as a first step towards D&I promotion.

Reasons For Award-Winner Selection

Promoting D&I by viewing acquisition of diverse human talents and their successes as essential for realizing their corporate concept. While promoting company-wide initatives with the "DE&I (Diversity, Equity & Inclusion) Promotion Committee", encouraging independent activities appropriate to onsite challenges through "DE&I projects" at each department. Further expansion in the number of female managers is expected down the road.

Highly Regarded Measures/Initiatives
1) Top management commitment and promotional framework for D&I
- Promoting D&I by regarding acquisition and retention of diverse human talents and their successes as essential to evolve the "hhc (human health care)" concept and realize an "hhceco company"
- Promoting activities by division, setting up "DE&I Projects" for global functions, such as corporate, R&D and manufacturing operations as well as each regional function, in parallel with implementing the "DE&I Promotion Committee" throughout the company.
- Plans to introduce a new personnel assessment system from FY 2023, which utilizes a behavioral assessment item "Diversity & Synergy" to further focus on diversity.

2) Developing female leaders
- Implementing E-Win (Eisai Women's Innovative Network) program to encourage personal growth and foster career awareness/aspirations

3) Reforming corporate culture/promoting increased awareness
- Promoting dialogues within the organization by leveraging monthly engagement survey

Eisai's corporate concept (also known as the hhc Concept) is to give first thought to patients and the people in the daily living domain, and increase the benefits that healthcare provides to them as well as meet their diversified healthcare needs worldwide. Eisai aims to realize the spiral of knowledge generated by diversity, regardless of differences in nationality, gender, age, etc., leading to the creation of innovation. Eisai also acquired third party appraisals including "Platinum Kurumin", an accreditation for organizations implementing high level parenting support by Ministry of Health, Labour and Welfare, as well as "the New Diversity Management Selection 100" and "Health & Productivity Management Outstanding Organizations" by Ministry of Economy, Trade and Industry.

Eisai is promoting DE&I throughout the company to ensure it has the diversity to meet increasingly diverse needs of patients and the people in the daily living domain.

For more information about Eisai's DE&I promotion, please visit it's corporate website.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2023/news202318.html.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 18 April 2024, 10:53 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, 17 April 2024, 16:17 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
2024年4月17日 10時00分 JST
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
Wednesday, 3 April 2024, 16:24 JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Monday, 1 April 2024, 9:39 JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575